Summary: Cigna Healthcare modified its molecular and proteomic diagnostic testing coverage policy for hematology and oncology indications (policy 0520), effective May 16, 2026. Here's what billing teams need to know before that date.
This update touches one of the more financially significant areas of oncology billing. Molecular and proteomic testing carries high per-claim dollar values, and Cigna's coverage policy for these tests directly determines what gets paid and what gets denied. The policy document does not list specific CPT or HCPCS codes in the data available at this time — but the scope of policy 0520 is broad enough that your oncology and hematology billing team should treat this as a high-priority review item before May 16, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Molecular and Proteomic Diagnostic Testing for Hematology and Oncology Indications |
| Policy Code | 0520 |
| Change Type | Modified |
| Effective Date | May 16, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Medical Oncology, Pathology, Laboratory Medicine |
| Key Action | Pull and review the full 0520 policy document before May 16, 2026, and audit any active authorizations tied to molecular or proteomic testing for oncology patients |
Cigna Molecular and Proteomic Diagnostic Testing Coverage Criteria and Medical Necessity Requirements 2026
The Cigna molecular and proteomic diagnostic testing coverage policy under policy 0520 governs a wide category of tests. This includes tumor profiling, genomic sequencing panels, proteomic assays, and related molecular diagnostics ordered in the context of hematologic malignancies and solid tumor oncology.
Medical necessity is the central lever in this policy. Cigna evaluates these tests based on whether the results will directly inform treatment decisions for the patient's specific diagnosis — not just whether a test is clinically available or commonly ordered. That distinction matters enormously in claim adjudication.
The real issue with policies like 0520 is scope creep in ordering. Oncologists order broad molecular panels because the information is useful, but Cigna's coverage policy draws a line between "useful" and "medically necessary for this patient at this point in treatment." If your ordering providers aren't documenting the treatment decision link explicitly, your denial rate on these claims will be higher than it needs to be.
Prior authorization is a consistent requirement for most molecular and proteomic testing under Cigna policies in this category. Check the current prior auth requirements for each specific test type before May 16, 2026, because modifications to the policy can shift which tests require prior auth and which can be billed directly.
Reimbursement for these tests is also contingent on proper diagnosis coding. The test must be ordered for a covered hematologic or oncologic indication, and the documentation in the medical record must connect the test to the patient's active diagnosis and treatment plan.
Cigna Molecular and Proteomic Testing Exclusions and Non-Covered Indications
Cigna consistently classifies certain molecular and proteomic tests as experimental or investigational. This is where a significant portion of claim denials occur in oncology billing.
Tests that lack sufficient clinical evidence to show they change patient management outcomes are typically excluded from coverage. Predictive or risk-stratification assays — tests that tell you something about future cancer risk rather than informing treatment of an active malignancy — are frequently designated as not medically necessary under policies like 0520.
Proteomic profiling that goes beyond what is needed to select a specific approved therapy is another common exclusion. If a test generates more data than the treatment decision requires, Cigna may deny it as not medically necessary even if the test itself is FDA-cleared.
Research-use testing, tests conducted outside of clinical necessity for registry or data collection purposes, and tests without peer-reviewed evidence supporting clinical utility are also exclusion categories you should expect under a policy like 0520. If your pathology or lab team is billing tests ordered primarily for investigational or research-adjacent purposes, those claims are at high risk for denial.
Coverage Indications at a Glance
The specific indications covered or excluded under the May 16, 2026 modification are not published in the currently available policy data. The table below reflects the general framework for how Cigna structures coverage under policy 0520. Confirm exact indication-level coverage against the full policy document at app.payerpolicy.org/p/cigna/mm_0520_coveragepositioncriteria_tumor_profiling. before billing.
| Indication Category | Likely Status | Notes |
|---|---|---|
| Tumor profiling for active solid tumor malignancy | Covered when criteria met | Medical necessity documentation required; prior authorization typically required |
| Molecular testing for hematologic malignancy | Covered when criteria met | Diagnosis must be confirmed; test must inform active treatment selection |
| Broad genomic sequencing panels (e.g., comprehensive tumor panels) | Covered with restrictions | Coverage often limited to specific lines of therapy or specific diagnoses; verify prior auth |
| Proteomic assays for treatment selection | Covered or Experimental depending on test | Evidence base determines coverage; check policy for specific assay categories |
| Predictive or risk-stratification testing in non-cancer patients | Not Covered / Experimental | Cigna typically excludes tests not tied to active malignancy management |
| Tests without peer-reviewed clinical utility evidence | Experimental / Not Covered | Commonly denied; document rationale thoroughly if billing |
| Research or registry-use molecular testing | Not Covered | No reimbursement for tests ordered primarily for research purposes |
Cigna Molecular and Proteomic Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull the full 0520 policy document now. The effective date of May 16, 2026 gives you a window to act. Go to the source at Cigna's coverage policy portal and download the updated 0520 document. Read the modification notes — policy changes at this level often involve shifts in which specific test categories meet medical necessity criteria. |
| 2 | Audit your active prior authorizations for molecular and proteomic tests. Any authorization issued before the effective date of May 16, 2026 may need to be revalidated against the new criteria. Don't assume an active auth carries through a policy modification without checking. |
| 3 | Review your documentation templates with your clinical team. Molecular and proteomic diagnostic testing billing lives or dies on the medical record. The ordering provider must document why this specific test is necessary for this patient's treatment decision — not just that the test was ordered. Update your order templates to prompt that documentation before May 16, 2026. |
| 4 | Identify claims in progress that could be affected. If you have claims currently in adjudication or on appeal that involve molecular or proteomic testing for hematology and oncology patients, flag them. A policy modification that takes effect mid-adjudication can shift the outcome. Talk to your billing consultant about how to handle in-flight claims around the effective date. |
| 5 | Update your charge capture process for any new or reclassified test categories. If the policy modification reclassifies specific tests from covered to experimental — or vice versa — your charge capture needs to reflect that before May 16, 2026. A claim denial from a reclassified test is expensive and avoidable. |
| 6 | Talk to your compliance officer before billing complex or edge-case molecular panels. If you're not sure whether a specific assay still meets Cigna's medical necessity criteria under the modified policy, get a compliance review before you bill. Claim denial and recoupment risk is high in this category. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Molecular and Proteomic Testing Under Cigna Policy 0520
The policy data available for this modification does not include a published list of specific CPT, HCPCS, or ICD-10 codes. This is not unusual for a policy of this scope — Cigna's 0520 policy historically covers a broad range of molecular diagnostic codes, and the specific code list is embedded in the full policy document rather than the modification summary.
Do not rely on previously known code lists without verifying against the updated May 16, 2026 policy. Modifications to policies like 0520 frequently add or remove codes from covered and non-covered categories.
What to Do About the Code Gap
Pull the full policy document from Cigna's medical policy portal. The 0520 policy typically includes a detailed list of covered and non-covered codes, grouped by clinical category. That list is the billing source of truth — not this summary, and not your previous authorization records.
If you have a Cigna provider relations contact or a dedicated account representative, request the updated code attachment for policy 0520 directly. Many Cigna policy modifications include a supplemental code list that doesn't appear in the public-facing summary.
Your laboratory billing team should cross-reference the updated code list against your current test menu. Any test you offer that appears in the policy's non-covered or experimental category is a prospective denial. Build that into your pre-billing workflow now.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.